Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Paterson

Showing results (101-110 of 1,015) with videos related to

Pageof 102
Sort By:
Chest|September 18, 2007
Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumoniaBrian A Potoski, David L Paterson
Expert Review of Anti-Infective Therapy|March 26, 2015
Multidrug-resistant Escherichia coli in Asia: epidemiology and managementHanna E Sidjabat, David L Paterson
Infectious Disease Clinics of North America|October 4, 2020
Multidrug-Resistant Bacteria in the Community: An UpdateDavid van Duin, David L Paterson
Diagnostic Microbiology and Infectious Disease|April 4, 2017
Increased risk of death with recurrent Pseudomonas aeruginosa bacteremiaK L McCarthy, D L Paterson
The Lancet. Infectious Diseases|February 1, 2017
China's antibiotic resistance problemsDavid L Paterson, David van Duin
JAMA Network Open|January 23, 2024
"Real-World" Evidence, Target Trial Emulation, and Randomized Clinical Trials-Which Data Should Clinicians Rely on When Choosing Antibiotics?David L Paterson, Helmi Bin Sulaiman
Internal Medicine Journal|April 8, 2024
Epidemiology and clinical significance of carbapenemases in Australia: a narrative reviewAbdullah Tarik Aslan, David L Paterson
Internal Medicine Journal|July 27, 2006
Multidrug-resistant Acinetobacter: a threat to the antibiotic eraA Y Peleg, D L Paterson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2006
A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organismsJesus Rodriguez-Baño, David L Paterson
Infection Control and Hospital Epidemiology|September 27, 2003
More evidence of the benefits of rational antimicrobial use in clinical practiceDavid L Paterson, Joseph G McCormack
Pageof 102

Showing results (101-110 of 1,015) with videos related to

Sort By:
Pageof 102
Chest|September 18, 2007
Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumoniaBrian A Potoski, David L Paterson
Expert Review of Anti-Infective Therapy|March 26, 2015
Multidrug-resistant Escherichia coli in Asia: epidemiology and managementHanna E Sidjabat, David L Paterson
Infectious Disease Clinics of North America|October 4, 2020
Multidrug-Resistant Bacteria in the Community: An UpdateDavid van Duin, David L Paterson
Diagnostic Microbiology and Infectious Disease|April 4, 2017
Increased risk of death with recurrent Pseudomonas aeruginosa bacteremiaK L McCarthy, D L Paterson
The Lancet. Infectious Diseases|February 1, 2017
China's antibiotic resistance problemsDavid L Paterson, David van Duin
JAMA Network Open|January 23, 2024
"Real-World" Evidence, Target Trial Emulation, and Randomized Clinical Trials-Which Data Should Clinicians Rely on When Choosing Antibiotics?David L Paterson, Helmi Bin Sulaiman
Internal Medicine Journal|April 8, 2024
Epidemiology and clinical significance of carbapenemases in Australia: a narrative reviewAbdullah Tarik Aslan, David L Paterson
Internal Medicine Journal|July 27, 2006
Multidrug-resistant Acinetobacter: a threat to the antibiotic eraA Y Peleg, D L Paterson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2006
A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organismsJesus Rodriguez-Baño, David L Paterson
Infection Control and Hospital Epidemiology|September 27, 2003
More evidence of the benefits of rational antimicrobial use in clinical practiceDavid L Paterson, Joseph G McCormack
Pageof 102